{"resourceType":"ValueSet","id":"2.16.840.1.113762.1.4.1116.388","meta":{"versionId":"4","lastUpdated":"2018-04-03T15:48:57.000-04:00"},"url":"http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113762.1.4.1116.388","version":"20171129","name":"No Adjuvant Hormonal Therapy Prostate","status":"active","date":"2017-11-29T01:00:05-05:00","publisher":"American Society of Clinical Oncology Steward","compose":{"include":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","concept":[{"code":"1P","display":"Performance Measure Exclusion Modifier due to Medical Reasons"},{"code":"2P","display":"Performance Measure Exclusion Modifier due to Patient Reasons"},{"code":"4164F","display":"Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"}]}]},"expansion":{"identifier":"urn:uuid:de8257f6-4ab4-4a07-9c5f-04bd1f8ad94b","timestamp":"2022-06-10T10:12:27-04:00","total":3,"offset":0,"parameter":[{"name":"count","valueInteger":1000},{"name":"offset","valueInteger":0}],"contains":[{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"1P","display":"Performance Measure Exclusion Modifier due to Medical Reasons"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"2P","display":"Performance Measure Exclusion Modifier due to Patient Reasons"},{"system":"http://www.ama-assn.org/go/cpt","version":"2021","code":"4164F","display":"Adjuvant (ie, in combination with external beam radiotherapy to the prostate for prostate cancer) hormonal therapy (gonadotropin-releasing hormone [GnRH] agonist or antagonist) prescribed/administered (PRCA)"}]}}